Small Cell Lung Cancer Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

The Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Small Cell Lung Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Small Cell Lung Cancer Market.

Some of the key takeaways from the Small Cell Lung Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years. 
• Small Cell Lung Cancer companies working in the treatment market are  CSPC ZhongQi Pharmaceutical Technology, Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical Co, Amgen, BeiGene, Sorrento Therapeutics, and others, are developing therapies for the Small Cell Lung Cancer treatment 

• Emerging Small Cell Lung Cancer therapies such as – SYHA 1807, AK104, APG 1252, BNT 411, QL1706, Tarlatamab, Tislelizumab, Socazolimab, and others are expected to have a significant impact on the Small Cell Lung Cancer market in the coming years.   
• In March 2022, Luye Pharma Group announced that it has filed a New Drug Application (NDA) in Hong Kong, China for Lurbinectedin, for the treatment of adult patients with metastatic Small-cell Lung Cancer (SCLC) with disease progression on or after receiving platinum-based chemotherapy. Lurbinectedin is an innovative oncology drug licensed to Luye Pharma by PharmaMar
• In March 2022, Harpoon Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a delta-like ligand 3- (DLL3) targeting TriTAC®, for the treatment of Small-cell Lung Cancer (SCLC). A Phase 1/2 clinical trial is currently ongoing for HPN328 in the SCLC patient population
• In March 2022, Akeso, Inc. announced that it has entered into a collaboration agreement with Shenzhen Chipscreen Biosciences, Ltd. (SHA Code 688321) to conduct a Phase Ib/II clinical study of combination therapy of Cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104) and Chiauranib (a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor) in patients with ES-SCLC which progressed on combination therapy of platinum-based chemotherapy and PD-(L)1 inhibitor as first-line treatment
• In January 2022, Genprex, Inc. announced that it has expanded its oncology research and development pipeline to include Small-cell Lung Cancer (SCLC) as an additional disease indication for its lead drug candidate, REQORSA™ Immunogene Therapy
• In July 2021, Sorrento Therapeutics initiated a Phase III, randomized, double-blind placebo-controlled study of Carboplatin Plus Etoposide with or without ZKAB001 (Anti-PD-L1 Antibody) in patients with untreated extensive stage Small Cell Lung Cancer

Small Cell Lung Cancer Overview

Small cell lung cancer is characterized as a neuroendocrine carcinoma because the cancer cells have features of nerve cells and endocrine (hormone-secreting) cells. Endocrine tissue is specialized tissue that contains hormone-secreting cells. These hormones have a variety of functions within the body.

Get a Free Sample PDF Report to know more about Small Cell Lung Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight

Emerging Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

• RP12146: Rhizen Pharmaceuticals
• SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
• AK104: Akeso
• APG 1252: Ascentage Pharma
• BNT 411: BioNTech
• QL1706: Qilu Pharmaceutical Co
• Tarlatamab: Amgen
• Tislelizumab: BeiGene
• Socazolimab: Sorrento Therapeutics

Route of Administration

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Small Cell Lung Cancer Pipeline Therapeutics Assessment

• Small Cell Lung Cancer Assessment by Product Type
• Small Cell Lung Cancer By Stage and Product Type
• Small Cell Lung Cancer Assessment by Route of Administration
• Small Cell Lung Cancer By Stage and Route of Administration
• Small Cell Lung Cancer Assessment by Molecule Type
• Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight’s Small Cell Lung Cancer Report covers around 100+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Small Cell Lung Cancer product details are provided in the report. Download the Small Cell Lung Cancer pipeline report to learn more about the emerging Small Cell Lung Cancer therapies

Some of the key companies in the Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for Small Cell Lung Cancer are – Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Aileron Therapeutics, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, Chipscreen Biosciences, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, Amgen, Bristol-Myers Squibb, Genentech, Sorrento Therapeutics, DAIICHI SANKYO COMPANY, BioNTech, Harpoon Therapeutics, Genprex, Inc., Tarveda Therapeutics, Taizhou HoudeAoke Biomedical Co., Ltd., BeiGene, HaiHe Biopharma, Kartos Therapeutics, Inc., Boehringer Ingelheim, Y-mAbs Therapeutics, CStone Pharmaceuticals, EpicentRx, Inc., Pfizer, and many others.

Small Cell Lung Cancer Pipeline Analysis:

The Small Cell Lung Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment.
• Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Small Cell Lung Cancer drugs and therapies

Small Cell Lung Cancer Pipeline Market Drivers

• Rising incidence of Small Cell Lung Cancer, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Small Cell Lung Cancer Market.

Small Cell Lung Cancer Pipeline Market Barriers

• However, the management of Small Cell Lung Cancer (SCLC) is problematic due to the aggressive nature of this type of cancer, rise in cost of treatment, poor prognosis of the disease in comparison with non-small cell lung cancer and other factors are creating obstacles in the Small Cell Lung Cancer Market growth.

Scope of Small Cell Lung Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Small Cell Lung Cancer Companies: CSPC ZhongQi Pharmaceutical Technology, Akeso, Ascentage Pharma, BioNTech, Qilu Pharmaceutical Co, Amgen, BeiGene, Sorrento Therapeutics, and others
• Key Small Cell Lung Cancer Therapies: SYHA 1807, AK104, APG 1252, BNT 411, QL1706, Tarlatamab, Tislelizumab, Socazolimab, and others
• Small Cell Lung Cancer Therapeutic Assessment: Small Cell Lung Cancer current marketed and Small Cell Lung Cancer emerging therapies
• Small Cell Lung Cancer Market Dynamics: Small Cell Lung Cancer market drivers and Small Cell Lung Cancer market barriers 

Request for Sample PDF Report for Small Cell Lung Cancer Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services